Entrez PubMed
Overview
Help | FAQ
New/Noteworthy
PubMed Services
Journal Browser
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Old
PubMed
Related
Resources
Order Documents
Grateful
Med
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
Privacy Policy
|
 |
-
Herceptin (trastuzamab) in advanced breast
cancer.
Stebbing J, Copson E, O'Reilly S
The Royal Marsden Hospital, London, U.K.
[Record supplied
by publisher]
Herceptin (trastuzamab, Genentech, San Francisco,
CA, USA) prolongs survival in metastatic breast cancer patients whose
tumours overexpress the HER2/neu protein. Compared with chemotherapy
alone, patients receiving chemotherapy and Herceptin have a
significantly longer time to progression, a higher response rate and a
longer duration of response. These effects are most marked in first-line
treatment of metastatic disease. The addition of Herceptin is associated
with few additional side-effects, apart from cardiac toxicity in
patients concurrently receiving anthracyclines. As such, it seems
reasonable for Herceptin to become considered as one of the routine
treatment options in metastatic breast cancer. It would therefore be
appropriate for HER2 status testing to be incorporated into the
assessment of all patients with metastatic disease. The use of this
medication will be limited by its cost. Furthermore, data are lacking on
appropriate treatments durations in responders. Copyright 2000 Harcourt
Publishers Ltd.
PMID: 10913383
|